AstraZeneca PLC has unveiled third-quarter results Nov. 9 which were in line with expectations and also focused on the advances its cancer treatments have been making in the clinic and commercially.
One treatment that received much attention on conference calls to discuss the results was the PD-1/L1 inhibitor Imfinzi (durvalumab), a...








